Bookmark and Share

Texas Oncology (BSDM) Acquires Hyperthermia System from BSD Medical

SALT LAKE CITY–(BUSINESS WIRE)–BSD Medical Corporation (NASDAQ:BSDMNews) (the “Company” or “BSD”) announced today that Texas Oncology has acquired the BSD-500 Hyperthermia System (BSD-500). Texas Oncology is an affiliate of the United Network of US Oncology, the nation’s largest network of community-based oncologists devoted to advancing cancer care and improving the cancer patient experience. The acquisition of the BSD-500 by Texas Oncology significantly increases the number of patients who will have access to hyperthermia treatment.

“We have known for years that hyperthermia was a promising treatment against cancer in the laboratory. Thanks to many dedicated scientists and clinicians, we now have very good clinical data and an excellent delivery device to offer our patients. Texas Oncology, along with US Oncology, is very excited to bring this technology to our patients and our network of doctors,” said Barry N. Wilcox, MD, Chief of Radiation Oncology at Baylor University Medical Center and Texas Oncology physician.

Texas Oncology delivers high-quality cancer care with leading-edge technology and provides advanced treatment and therapy options to help patients in their fight against cancer. Texas Oncology, a pioneer in community-based cancer care, is an independent oncology practice with more than 300 physicians serving 100 sites of service throughout Texas and Southeastern New Mexico. Texas Oncology patients have the opportunity to take part in some of the most promising clinical trials in the nation for a broad range of cancers. Through its affiliation with US Oncology and the US Oncology Research network, Texas Oncology participates in innovative clinical trials from Phase I through Phase IV, and has played a role in the development of 42 Food and Drug Administration (FDA) approved cancer therapies.

The United Network of US Oncology is a nationwide physician network focused on advancing cancer care at the community level and on delivering the best cancer care for patients. US Oncology, and the more than one thousand physicians of the United Network of US Oncology, are committed to eradicating cancer through the collective use of their expertise, deep resources, and diverse cancer-fighting capabilities. With a focus on bringing patients world-class evidence-based treatments, the latest clinical trials in the community setting, and healthcare technology to enhance the overall patient experience, the United Network of US Oncology offers the vision and resources to help ensure the long-term success of community-based cancer care.

The BSD-500 Hyperthermia System is used to deliver therapeutic heating (hyperthermia) using either non-invasive (external) hyperthermia, which is delivered using antennas placed over the tumor, or interstitial hyperthermia, which is delivered using antennas that are inserted into the tumor, or a combination of both. The BSD-500 has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), which is the standard FDA approval required to market Class III medical devices in the United States, for the use of hyperthermia alone or in conjunction with radiation therapy for the treatment of certain tumors.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical’s website at

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.

Wednesday, September 22nd, 2010 Uncategorized
Top Small Cap Market News